CNS Pharmaceuticals Inc. (NASDAQ: CNSP) is -53.92% lower on its value in year-to-date trading and has touched a low of $1.26 and a high of $5.62 in the current 52-week trading range. The CNSP stock was last observed hovering at around $2.10 in the last trading session, with the day’s loss setting it -0.28% off its average median price target of $8.00 for the next 12 months. It is also 83.45% off the consensus price target high of $11.00 offered by 3 analysts, but current levels are 74.0% higher than the price target low of $7.00 for the same period.
Gold bugs are shouting from the rooftops in excitement, but that doesn’t mean you rush out and just buy any gold stock…That’s why we laid out The 2021 Ultimate Gold Portfolio – to dissect the treasure from the trash.
Currently trading at $1.82, the stock is -23.17% and -14.13% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 3.84 million and changing -13.33% at the moment leaves the stock -22.01% off its SMA200. CNSP registered -55.93% loss for a year compared to 6-month gain of -19.11%. The firm has a 50-day simple moving average (SMA 50) of $2.2517 and a 200-day simple moving average (SMA200) of $2.0565.
The stock witnessed a -23.21% loss in the last 1 month and extending the period to 3 months gives it a 3.41%, and is -16.51% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 21.71% over the week and 12.67% over the month.
Distance from 52-week low is 44.65% and -67.62% from its 52-week high.
CNS Pharmaceuticals Inc. (CNSP) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for CNS Pharmaceuticals Inc. (CNSP) is a “Buy”. 3 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 3 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
CNS Pharmaceuticals Inc. is expected to release its quarterly report on 03/12/2021 and quarterly earnings per share for the current quarter are estimated at -$0.12.The EPS is expected to grow by 39.60% this year.
CNS Pharmaceuticals Inc. (CNSP) Top Institutional Holders
12 institutions hold shares in CNS Pharmaceuticals Inc. (CNSP), with 10.07M shares held by insiders accounting for 60.48% while institutional investors hold 1.64% of the company’s shares. The shares outstanding are 16.48M, and float is at 6.58M with Short Float at 1.04%. Institutions hold 0.65% of the Float.
The top institutional shareholder in the company is Essex Investment Management Co Inc with over 61563.0 shares valued at $0.11 million. The investor’s holdings represent 0.37% of the CNSP Shares outstanding. As of Sep 29, 2020, the second largest holder is Morgan Stanley with 12500.0 shares valued at $22000.0 to account for 0.08% of the shares outstanding. The other top investors are Integrated Advisors Network LLC which holds 10700.0 shares representing 0.06% and valued at over $18832.0, while Alpha Cubed Investments, LLC holds 0.06% of the shares totaling 10000.0 with a market value of $17600.0.
CNS Pharmaceuticals Inc. (CNSP) Insider Activity
The most recent transaction is an insider purchase by Downs Christopher, the company’s Chief Financial Officer. SEC filings show that Downs Christopher bought 142,000 shares of the company’s common stock on Aug 24 at a price of $2.04 per share for a total of $0.29 million. Following the purchase, the insider now owns 0.14 million shares.